14 Jun
2021

The IP dangers in life sciences collaborations and how to avoid them

IAM asked a panel of experts how biotech and pharma innovators can best overcome the distinctive IP challenges associated with research collaborations. They identified six key areas to focus on

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth